Sagimet touts China partner Ascletis' Phase 3 FASN inhibitor data in acne
Sagimet Biosciences' FASN inhibitor denifanstat succeeded in a China-based Phase 3 trial in moderate-to-severe acne that was run by its local partner Ascletis. While that trial is for the Chinese market and won't be used ...
Sagimet Biosciences' FASN inhibitor denifanstat succeeded in a China-based Phase 3 trial in moderate-to-severe acne that was run by its local partner Ascletis.
While that trial is for the Chinese market and won't be used ...
